In a retrospective, multicenter study, ICI was used as second-line or later treatment for 9 patients with advanced RET fusion NSCLC, and the researchers reported that 10% of the enrolled patients experienced 3–5 grade immune-mediated adverse events (AEs) (most commonly colitis) (Meng et al., 2022). This evidence concerns the gene RET and colitis.